Skip to content

PRELUDE THERAPEUTICS INC

PRLD

CIK 0001678660

← back to feed
Revenue (TTM)
$14.08M
+73.4% YoY Q1 May 2026
Net Income (TTM)
−$93.43M
+21.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.22
+23.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-720.1%
Q1 May 2026
Net Margin
-663.5%
Q1 May 2026
Free Cash Flow (TTM)
−$118.99M
Q1 May 2026
Cash
$21.76M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
79.65M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings